Adenocarcinoma
190
20
26
96
Key Insights
Highlights
Success Rate
77% trial completion
Published Results
39 trials with published results (21%)
Research Maturity
96 completed trials (51% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
14.7%
28 terminated out of 190 trials
77.4%
-9.1% vs benchmark
12%
23 trials in Phase 3/4
41%
39 of 96 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 96 completed trials
Clinical Trials (190)
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
Use of Tracking Devices to Locate Abnormalities During Invasive Procedures
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
Anatomical-Clinical Base of Adenocarcinoma Pancreatic
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Prospective Data Collection Initiative on Thoracic Malignancies
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy
Treatment of Multifocal Lung Adenocarcinoma
Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression.
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies
EchoTip AcuCore Post-Market Clinical Study